Skip to main navigation menu Skip to main content Skip to site footer

Primary neuroendocrine carcinoma of the mammary gland, hormone receptor positive with high histological grade differentiation : case report and review of the literature.

Carcinoma neuroendocrino primario de la glándula mamaria, reporte de caso y revisión de la literatura.



Open | Download

How to Cite

1.
Bonilla González CE, Russi Noguera JA, Gómez C, Lasso M. Primary neuroendocrine carcinoma of the mammary gland, hormone receptor positive with high histological grade differentiation : case report and review of the literature. Rev. colomb. hematol. oncol. [Internet]. 2020 Aug. 1 [cited 2025 Dec. 5];7(2):42-7. https://doi.org/10.51643/22562915.113

Download Citation

Citations


Section
Clinic cases

How to Cite
1.
Bonilla González CE, Russi Noguera JA, Gómez C, Lasso M. Primary neuroendocrine carcinoma of the mammary gland, hormone receptor positive with high histological grade differentiation : case report and review of the literature. Rev. colomb. hematol. oncol. [Internet]. 2020 Aug. 1 [cited 2025 Dec. 5];7(2):42-7. https://doi.org/10.51643/22562915.113

Dimensions
PlumX

Carlos Eduardo Bonilla González ,

MD., Esp. Oncología Clínica

Grupo de Oncología Clínica


July Andrea Russi Noguera ,

MD., Esp: Oncología Clínica


Carolina Gómez,

MD., Esp. Medicina Interna.


Miller Lasso,

MD., Esp. Medicina Interna.


Primary breast neuroendocrine carcinoma is a rare subtype of breast neuroendocrine tumors. Given the low incidence of this disease, most published articles in the literature are case series, therefore, the results regarding the biologic behaviour and prognosis are divergent. The main characteristic of this group of tumors is the histopathological expression of both epithelial and endocrine immunohistochemical markers to a greater or lesser degree, which in some cases can even coexist in the same cell. Hereby we present the case of a female patient with a breast neuroendocrine carcinoma, with a revision of clinical features and treatment options.


Article visits 889 | PDF visits 530


Downloads

Download data is not yet available.
  1. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO Classification of Tumours of the Breast, Volume 4. Lyon, France. IARC, No 4. IPress.2012.
  2. Bosotenau M, Bosotenau C, Deacu M, Aschie M. Morphological and immunohistochemical characteristics of a gastric amphicrine tumor: differential diagnosis considerations. Rom J Morphol Embryol. 2011;52(1) Suppl:485-8. PMID: 21424098
  3. Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology [Internet].2002;40:211–214. https://doi.org/10.1046/j.1365-2559.2002.01327.x
  4. Miramedi A, Pinder SE, Lee AHS et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology [Internet]. 2002;40; 215±222. https://doi.org/10.1046/j.1365-2559.2002.01336.x
  5. Tavassoli FA, Devilee P. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series, 4, 3rd edition. Lyon, France: IARC Press; 2003.
  6. Wang J, Wei B, Albarracín CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population based study from the surveillance, epidemiology and end results (SEER) database, BMC Cancer [Internet]. 2014;14: 147. https://doi.org/10.1186/1471-2407-14-147
  7. Angarita FA, Rodríguez JL, Meek E, Sánchez JO, Tawil M, Torregrosa L. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol [Internet].2013;11:128. https://dx.doi.org/10.1186%2F1477-7819-11-128
  8. Gunhan-Bilgen I, Zekioglu O, Ustun EE, Memis A, Erhan Y. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol [Internet]. 2003;13:788–793, https://doi.org/10.1007/s00330-002-1567-z
  9. Park YM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol [Internet]. 2014; 203: W221–W230,. https://doi.org/10.2214/ajr.13.10749
  10. Righi L, Sapino A, Marchio C, Papotti M, Bussolati G. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol [Internet]. 2010;27:69–76, https://doi.org/10.1053/j.semdp.2009.12.003
  11. Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci [Internet]. 1991;16(1):27-30. https://doi.org/10.1016/0968-0004(91)90012-k
  12. Silva-Barbosa C, Álzate-Meza M, Messa-Botero O, Chinchilla-Olaya S, Romero-Rojas A. Carcinoma anficrino de glándula mamaria. Reporte de un caso inusual. Rev Colomb Cancerol [Internet]. 2015;19(3):173-179. http://dx.doi.org/10.1016/j.rccan.2015.04.006.
  13. Alkaied H, Harris K, Azab B, Dai Q: Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol [Internet]. 2012; 29:2613–2618. https://doi.org/10.1007/s12032-012-0222-z
  14. [14] Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Patho [Internet]. 2001;14:768–776. https://doi.org/10.1038/modpathol.3880387
  15. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol [Internet]. 1999;17:1442–1448. https://doi.org/10.1200/jco.1999.17.5.1442
  16. Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H, Reis-Filho JS. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol [Internet]. 2009;22(11):1401-1414. https://doi.org/10.1038/modpathol.2009.112
  17. Van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M. The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast. [Internet] 2004;13(4):329-33. https://doi.org/10.1016/j.breast.2003.11.008
  18. Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer [Internet]. 2010;116(19):4463-73. https://doi.org/10.1002/cncr.25352
  19. Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann, Claire B, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology [Internet]. 2018;31,68–82. https://doi.org/10.1038/modpathol.2017.107
  20. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol [Internet]. 2008; 26:3063–3072. https://doi.org/10.1200/jco.2007.15.4377
  21. Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, et. al, Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. The Oncologist [Internet]. 2016;21:1–5. https://doi.org/10.1634/theoncologist.2015-0309
  22. Yildirim Y, Elagoz S, Koyuncu A, Aydin C, Karadayi K. Management of neuroendocrine carcinomas of the breast: A rare entity. Oncology Letters [Internet]. 2011;2: 887-890. https://dx.doi.org/10.3892%2Fol.2011.320
  23. Buttar A, Mittal K, Khan A, Bathini V. Effective Role of Hormonal Therapy in Metastatic Primary Neuroendocrine Breast Carcinoma. Clin Breast Cancer [Internet]. 2011;11(5):342-5. https://doi.org/10.1016/j.clbc.2011.02.006
  24. Savelli G, Zaniboni A, Bertagna F, Bosio G, Nisa L, et al. Peptide receptor radionuclide therapy (PRRT) in a patient affected by metastatic breast cancer with neuroendocrine differentiation. Breast Care (Basel) [Internet]. 2012;7: 408–410. https://doi.org/10.1159/000343612
Sistema OJS 3.4.0.7 - Metabiblioteca |